Skip to main content

Resources for Small Businesses

Click here to download presentations from the workshop on Federal Resources to Accelerate Commercialization, including presentations from many of the federal agencies listed below.

National Cancer Institute Resources & Collaborative Programs

NCI Experimental Therapeutics Program (NExT), provides access to anticancer drug discovery and development resources to help advance projects from initial discovery to proof-of-concept clinical trials

NCI PREVENT Program, enables the progression of novel cancer preventing interventions and biomarkers through preclinical development and towards clinical trials

Developmental Therapeutics Program (DTP) Open Chemical Repository Collection

The NCI DTP Open Chemical Repository Collection maintains a repository of synthetic compounds and pure natural products that are available to investigators for non-clinical research purposes. Over 20,000 vialed samples and 3,500 plates are shipped from the Repository to external investigators throughout the world annually. Repository collection is a uniquely diverse set of more than 200,000 compounds that have been either submitted to DTP for biological evaluation or, in some cases, synthesized under DTP auspices.

Importantly, investigators should note that chemical structures of these substances are those assigned by the originator of the material and in the vast majority of cases, the compounds have not been analyzed by DTP for accuracy of structure or for the purity of the sample. Compounds are available through a web-based ordering system.

For more information about the DTP Open Chemical Repository including ordering procedures, please visit:

NCI Clinical Assay Development Program (CADP)

The NCI Clinical Assay Development Program (CADP) is no longer accepting applications. The CADP provides tissue and laboratory resources for analytical and clinical validation of an assay to predict response to treatment or disease outcome. For more information on the program, you can visit CAPD here:

NCI Cancer Diagnosis Program (CDP): Human Biospecimen Resources

  • The Cooperative Human Tissue Network (CHTN) prospectively collects and provides human tissue specimens (malignant, benign, diseased and normal tissues) and pathology report data for use in basic discovery and translational cancer research. The procurement and processing of specimens varies according to the protocol of each individual investigator: fresh, frozen, or chemically-fixed. The CHTN also produces tissue microarrays from multiple tissue types to study cancer and other diseases. Isolation and distribution of the nucleic acids from the CHTN-procured specimens can also be performed to serve the investigator’s interest:
  • Cancer Diagnosis Program (CDP) Tissue Microarrays (TMAs):
    • Breast Cancer Progression and Prognostic TMAs were constructed using tissue and associated pathological and clinical outcome data from the Cooperative Breast Cancer Tissue Resource (CBCTR). The CDP Progression TMA is designed to permit comparisons of biomarker expression across three stages of disease (node-negative, node positive and metastatic). The CDP Prognostic TMA is designed for examination of biomarkers and correlation with survival and recurrence outcomes in stage I, II and III breast cancer. Both TMAs were designed to ensure high statistical power for evaluation and validation of breast cancer biomarkers.
    • Melanoma Progression TMA consists of 273 tissue specimens containing nevi, primary melanomas, metastatic melanoma to the lymph node, and visceral and dermal metastatic melanoma. This TMA is designed to investigate differences in expression of markers in various stages of melanoma progression and should be used as a screening array.
    • Colon Cancer Progression-Prognostic TMA has over 350 primary colon cancers and 100 control tissues and is designed for examination of associations of markers with tumor stage, clinical outcome, and other clinico-pathological variables in Stage I-IV colon cancer.
  • The NCI Specimen Resource Locator is a searchable database that helps researchers locate specimens for research. The database includes resources such as tissue banks and tissue procurement services with access to normal, benign, pre-cancerous and/or cancerous human tissue. The NCI Cooperative Group Banks associated with large Phase II and Phase III clinical trials have banked tumor specimens from large numbers of uniformly treated cancer patients with a variety of malignancies. Each group (ACOSOG, CALGB, COG, ECOG, GOG, NCCTG, NCIC-CTG, NSABP, RTOG, and SWOG) has a review process for research proposals. If proposals receive favorable reviews, specimens with clinical, treatment, and outcome data can be made available to researchers through collaborative arrangements. These well annotated specimens are most useful for clinical correlative studies in randomized uniformly treated patient populations. To access these specimens, interested investigators may visit the NCI Specimen Resource Locator Website at or contact the NCI Tissue Expediter at

NCI Cancer Imaging Program: The Cancer Imaging Archive (TCIA)

The NCI Cancer Imaging Program supports two archives of medical images of cancer accessible for public download. All images contained in the archives are stored in DICOM file format.

  • The National Biomedical Imaging Archive (NBIA) is available at The NBIA contains two CT Colonography collections and multiple collections from the Reference Image Database to Evaluate Therapy Response (RIDER).
  • The Cancer Imaging Archive (TCIA) is available at The TCIA contains the Lung Image Database Consortium image collection and a growing set of image collections linked to cases analyzed by The Cancer Genome Atlas, among others.

Frederick National Laboratory for Cancer Research (FNLCR), offers partnering opportunities providing a wide range of advanced technologies and platforms, including cancer model development, genetics & genomics, proteins & proteomics, clinical assay development, nanotechnology characterization, high-performance biomedical computing, and advanced biomedical imaging


Additional National Institutes of Health Resources & Programs

Click here to download presentations from the programs below at the workshop on Federal Resources to Accelerate Commercialization.


National Center for Advancing Translational Sciences (NCATS)


Federal Funding Opportunities for Cancer Technology

Click here to download presentations from the federal agencies below at the workshop on Federal Resources to Accelerate Commercialization.

Biomedical Advanced Research and Development Authority (BARDA)

Within the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services, BARDA provides a systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.

Congressionally Directed Medical Research Programs (CDMRP)
The CDMRP finds and funds the best research to target innovative research approaches, encourage high-impact research, integrate consumer participation at each level, and support unique goals of each program.

National Science Foundation (NSF) SBIR/STTR programs
The NSF SBIR program incentivizes and enables startups and small businesses to undertake R&D with high technical risk and high commercial reward.


Federal Resources and Programs for Small Businesses

Click here to download presentations from the federal agencies below at the workshop on Federal Resources to Accelerate Commercialization.

White House Startup America

United States Patent & Trademark Office (USPTO)

Center for Medicare and Medicaid Services (CMS)

Food and Drug Administration (FDA)


U.S. Small Business Administration Affordable Care Act Resources

The Affordable Care Act (ACA) includes a variety of measures specifically for small businesses. Learn about the key provisions of ACA with the following resources from the U.S. Small Business Administration (SBA).

For more information, visit